Skip to main content
. 2022 Apr 13;14(8):1949. doi: 10.3390/cancers14081949

Table 1.

Disease-free survival (DFS) and overall survival (OS) in early-stage NSCLC with EGFR mutations.

Study Year Kind of Study Patients (Total/EGFR) Stage DFS OS
Zhang et al. 2014 Meta-analysis 3337 (n.r.) I–III n.s. 1 n.s.
Yang et al. 2021 Retrospective 476 (260) I–III n.s. n.s.
Chen et al. 2021 Retrospective 338 (216) I n.s. positive
Jao et al. 2018 Retrospective 214 (46) I–III Negative n.s.

1 n.s.: not significant. n.r.: not reported.